BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

22377

543220

MAXHEALTH

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

MAX HEALTHCARE INS LTD performance

Today’s low

Today’s high

₹ 1088.60 ₹ 1124.90
₹ 1098.20

52 week low

52 week high

₹ 743.10 ₹ 1227.95
₹ 1098.20

Open Price

₹ 1124.90

Prev. Close

₹ 1107.40

Volume (Shares)

2112594.00

Total traded value

₹ 23200.50

Upper Circuit

₹ 1218.10

Lower Circuit

₹ 996.70

info

MAX HEALTHCARE INS LTD Share Price Update

As of the latest trading session, MAX HEALTHCARE INS LTD share price is currently at ₹ 1098.2, which is down by ₹ -9.20 from its previous closing. Today, the stock has fluctuated between ₹ 1088.60 and ₹ 1124.90. Over the past year, MAX HEALTHCARE INS LTD has achieved a return of 30.69 %. In the last month alone, the return has been 1.34 %. Read More...

MAX HEALTHCARE INS LTD fundamentals


  • Market cap (Cr)

    1,06,735.40

  • P/E Ratio (TTM)

    139.29

  • Beta

    0.79

  • Book Value / share

    81.72

  • Return on equity

    9.34%

  • EPS (TTM)

    8.40

  • Dividend yield

    0.14%

  • Net profit/quarter (Cr)

    138.24

info icon alternate text
  • Market cap (Cr)

    1,06,716.00

  • P/E Ratio (TTM)

    139.29

  • Beta

    0.77

  • Book Value / share

    81.72

  • Return on equity

    9.34%

  • EPS (TTM)

    8.40

  • Dividend yield

    0.14%

  • Net profit/quarter (Cr)

    138.24

info icon alternate text

MAX HEALTHCARE INS LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 697.40
Operating Expense 517.60
Net Profit 138.24
Net Profit Margin (%) 19.82
Earnings Per Share (EPS) 1.42
EBITDA 254.42
Effective Tax Rate (%) 30.24
Particulars SEP 2024 (Values in Cr)
Revenue 686.11
Operating Expense 501.47
Net Profit 231.30
Net Profit Margin (%) 33.71
Earnings Per Share (EPS) 2.00
EBITDA 358.18
Effective Tax Rate (%) 27.29
Particulars JUN 2024 (Values in Cr)
Revenue 621.39
Operating Expense 461.09
Net Profit 154.14
Net Profit Margin (%) 24.80
Earnings Per Share (EPS) 1.59
EBITDA 240.94
Effective Tax Rate (%) 24.12
Particulars MAR 2024 (Values in Cr)
Revenue 610.11
Operating Expense 457.26
Net Profit 241.77
Net Profit Margin (%) 39.62
Earnings Per Share (EPS) 2.49
EBITDA 337.20
Effective Tax Rate (%) 16.80
Particulars DEC 2023 (Values in Cr)
Revenue 590.75
Operating Expense 430.10
Net Profit 158.12
Net Profit Margin (%) 26.76
Earnings Per Share (EPS) 1.63
EBITDA 242.83
Effective Tax Rate (%) 22.23
Particulars MAR 2024 (Values in Cr)
Revenue 2341.36
Operating Expense 1747.62
Net Profit 687.26
Net Profit Margin (%) 29.35
Earnings Per Share (EPS) 7.07
EBITDA 1033.26
Effective Tax Rate (%) 20.54
Particulars MAR 2023 (Values in Cr)
Revenue 1904.66
Operating Expense 1485.69
Net Profit 694.31
Net Profit Margin (%) 36.45
Earnings Per Share (EPS) 7.16
EBITDA 728.26
Effective Tax Rate (%) -23.29
Particulars MAR 2022 (Values in Cr)
Revenue 1775.36
Operating Expense 1502.99
Net Profit 331.52
Net Profit Margin (%) 18.67
Earnings Per Share (EPS) 3.43
EBITDA 571.38
Effective Tax Rate (%) 17.22
Particulars MAR 2021 (Values in Cr)
Revenue 1030.78
Operating Expense 1073.08
Net Profit -164.45
Net Profit Margin (%) -15.95
Earnings Per Share (EPS) -1.91
EBITDA 56.73
Effective Tax Rate (%) -12.28
Particulars MAR 2020 (Values in Cr)
Revenue 59.26
Operating Expense 128.57
Net Profit -2.96
Net Profit Margin (%) -4.99
Earnings Per Share (EPS) -0.05
EBITDA 60.24
Effective Tax Rate (%) 4.51
Particulars MAR 2024 (Values in Cr)
Book Value / Share 86.51
ROE % 13.37
ROCE % 14.96
Total Debt to Total Equity 0.13
EBITDA Margin 29.28
Particulars MAR 2023 (Values in Cr)
Book Value / Share 76.31
ROE % 16.12
ROCE % 13.85
Total Debt to Total Equity 0.12
EBITDA Margin 28.56
Particulars MAR 2022 (Values in Cr)
Book Value / Share 64.79
ROE % 10.15
ROCE % 11.09
Total Debt to Total Equity 0.17
EBITDA Margin 25.45
Particulars MAR 2021 (Values in Cr)
Book Value / Share 58.37
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.40
EBITDA Margin 20.69
Particulars MAR 2020 (Values in Cr)
Book Value / Share 18.38
ROE % 8.03
ROCE % 9.77
Total Debt to Total Equity 1.29
EBITDA Margin 19.18
Particulars MAR 2024 (Values in Cr)
Book Value / Share 79.03
ROE % 9.34
ROCE % 11.64
Total Debt to Total Equity 0.07
EBITDA Margin 42.24
Particulars MAR 2023 (Values in Cr)
Book Value / Share 72.53
ROE % 10.40
ROCE % 8.49
Total Debt to Total Equity 0.08
EBITDA Margin 36.46
Particulars MAR 2022 (Values in Cr)
Book Value / Share 65.09
ROE % 5.41
ROCE % 6.89
Total Debt to Total Equity 0.08
EBITDA Margin 30.80
Particulars MAR 2021 (Values in Cr)
Book Value / Share 61.49
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.13
EBITDA Margin 24.75
Particulars MAR 2020 (Values in Cr)
Book Value / Share 53.52
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.25
EBITDA Margin 101.65
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1099.27
Total Assets 11999.94
Total Liabilities 11999.94
Total Equity 8408.14
Share Outstanding 971912408
Price to Book Ratio 10.38
Return on Assets (%) 8.81
Return on Capital (%) 11.07
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1468.07
Total Assets 10101.85
Total Liabilities 10101.85
Total Equity 7409.59
Share Outstanding 970922825
Price to Book Ratio 6.08
Return on Assets (%) 10.92
Return on Capital (%) 13.84
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 499.31
Total Assets 9189.13
Total Liabilities 9189.13
Total Equity 6282.47
Share Outstanding 969613455
Price to Book Ratio 5.33
Return on Assets (%) 6.58
Return on Capital (%) 8.63
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 652.92
Total Assets 8544.44
Total Liabilities 8544.44
Total Equity 5638.68
Share Outstanding 965945006
Price to Book Ratio 3.35
Return on Assets (%) -1.60
Return on Capital (%) -2.1
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 280.79
Total Assets 3824.38
Total Liabilities 3824.38
Total Equity 987.41
Share Outstanding 537244328
Price to Book Ratio 0.00
Return on Assets (%) 2.49
Return on Capital (%) 4.18
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 720.04
Total Assets 9068.87
Total Liabilities 9068.87
Total Equity 7680.76
Share Outstanding 971912408
Price to Book Ratio 10.38
Return on Assets (%) 7.57
Return on Capital (%) 8.57
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1231.46
Total Assets 8420.33
Total Liabilities 8420.33
Total Equity 7042.11
Share Outstanding 970922825
Price to Book Ratio 6.08
Return on Assets (%) 8.24
Return on Capital (%) 9.26
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 386.51
Total Assets 7811.76
Total Liabilities 7811.76
Total Equity 6311.38
Share Outstanding 969613455
Price to Book Ratio 5.33
Return on Assets (%) 4.24
Return on Capital (%) 4.93
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 610.99
Total Assets 7142.95
Total Liabilities 7142.95
Total Equity 5939.43
Share Outstanding 965945006
Price to Book Ratio 3.35
Return on Assets (%) -2.30
Return on Capital (%) -2.62
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 269.10
Total Assets 2511.06
Total Liabilities 2511.06
Total Equity 1246.04
Share Outstanding 537244328
Price to Book Ratio 0.00
Return on Assets (%) 1.11
Return on Capital (%) 1.36
Particulars MAR 2024 (Values in Cr)
Net Income 1365.32
Cash from Operations 1391.08
Cash from Investing -1285.45
Cash from Financing -263.74
Net change in Cash -427.39
Free Cash Flow 2177.02
Particulars MAR 2023 (Values in Cr)
Net Income 1063.72
Cash from Operations 1445.25
Cash from Investing -102.32
Cash from Financing -288.56
Net change in Cash 893.25
Free Cash Flow 1780.86
Particulars MAR 2022 (Values in Cr)
Net Income 738.90
Cash from Operations 849.58
Cash from Investing -763.80
Cash from Financing -294.17
Net change in Cash -317.45
Free Cash Flow 1402.92
Particulars MAR 2021 (Values in Cr)
Net Income -68.65
Cash from Operations 59.84
Cash from Investing -73.00
Cash from Financing 191.33
Net change in Cash 236.19
Free Cash Flow 178.26
Particulars MAR 2020 (Values in Cr)
Net Income 89.08
Cash from Operations 262.53
Cash from Investing -126.68
Cash from Financing 144.05
Net change in Cash 267.19
Free Cash Flow 351.27
Particulars MAR 2024 (Values in Cr)
Net Income 864.96
Cash from Operations 761.78
Cash from Investing -805.64
Cash from Financing -245.91
Net change in Cash -438.46
Free Cash Flow 1223.13
Particulars MAR 2023 (Values in Cr)
Net Income 563.14
Cash from Operations 784.72
Cash from Investing 301.69
Cash from Financing -54.47
Net change in Cash 943.69
Free Cash Flow 905.22
Particulars MAR 2022 (Values in Cr)
Net Income 400.49
Cash from Operations 490.19
Cash from Investing -669.65
Cash from Financing -161.48
Net change in Cash -383.77
Free Cash Flow 861.18
Particulars MAR 2021 (Values in Cr)
Net Income -146.46
Cash from Operations 201.33
Cash from Investing -365.61
Cash from Financing 412.41
Net change in Cash 271.27
Free Cash Flow 232.74
Particulars MAR 2020 (Values in Cr)
Net Income 27.88
Cash from Operations 123.87
Cash from Investing -192.61
Cash from Financing 329.36
Net change in Cash 264.86
Free Cash Flow 168.08
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 76.41 13.35 100103.60 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 75.38 183.85 4.73 141.28 51.01 / 98.70
SHREE PACETRONIX LTD. 70.00 14.58 1.87 25.20 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.68 0.00 2.57 27.88 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 83.30 12.22 100103.60 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 32.25 0.00 -17.27 24.09 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5560.50 29.47 6.24 6083.19 3750.00 / 6400.00

MAX HEALTHCARE INS LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1098.20 -0.83 redarrow
red-green-graph indicator
5 Bearish
11 Bullish
  • 5 Days 1099.40
  • 26 Days 1090.90
  • 10 Days 1098.60
  • 50 Days 1080.70
  • 12 Days 1098.20
  • 100 Days 1063.10
  • 20 Days 1094.40
  • 200 Days 1008.80
1109.07 PIVOT

First Support

1099.03

First Resistance

1117.43

Second Support

1090.67

Second Resistance

1127.47

Third Support

1080.63

Third Resistance

1135.83

RSI

51.35

ADX

34.06

MACD

7.27

Williams % R

-56.94

Commodity Channel Index (CCI)

21.15

Date

2025-04-30

Week

1267060.00

Same Day

1332225.00

Month

1526081.00

1 Year

0.80

3 Year

0.54

Over 1 Month

1.34%

down

Over 1 Year

30.69%

down

Over 3 Months

5.20%

down

Over 3 Years

41.03%

down

Over 6 Months

10.66%

down

Over 5 Years

57.93%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

MAX HEALTHCARE INS LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
3.93%
Promoter Holdings
23.73%
FII
54.73%
DII
17.58%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Abhay Soi 2.30717699E8 (23.73%) Shareholding of Promoter and Promoter Group
Government Of Singapore 5.5272339E7 (5.69%) Public Shareholding
New World Fund Inc 5.1780682E7 (5.33%) Public Shareholding
Smallcap World Fund, Inc 3.4469954E7 (3.55%) Public Shareholding
Hdfc Mutual Fund 1.707449E7 (1.76%) Public Shareholding
Sbi Mutual Fund 1.6875947E7 (1.74%) Public Shareholding
Monetary Authority Of Singapore 1.4454649E7 (1.49%) Public Shareholding
Motilal Oswal Mutual Fund 1.3260868E7 (1.36%) Public Shareholding
Canara Robeco Mutual Fund 1.248738E7 (1.28%) Public Shareholding
Government Pension Fund Global 1.0630634E7 (1.09%) Public Shareholding
Kotak Mutual Fund 1.0524081E7 (1.08%) Public Shareholding
Vanguard Total International Stock Index Fund 1.0493166E7 (1.08%) Public Shareholding
Kotak Funds - India Midcap Fund 1.0331746E7 (1.06%) Public Shareholding
Axis Mutual Fund 9952835.0 (1.02%) Public Shareholding
Hdfc Life Insurance Company Limited 9775139.0 (1.01%) Public Shareholding
Aditya Soi 60000.0 (0.01%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

MAX HEALTHCARE INS LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
08 Sep 2023 1.0 Final 08 Sep 2023 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
08 Sep 2023 1.0 Final 08 Sep 2023 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

MAX HEALTHCARE INS LTD Share Price

Max Healthcare Institute Limited was originally incorporated as 'Infinitum Technologies Private Limited' at New Delhi, India as a Private Limited Company dated June 18 ,2001. Pursuant to a Fresh Certificate of Incorporation dated June 28, 2002, the name of Infinitum Technologies Private Limited' was changed to Max Healthcare Institute Private Limited'. Thereafter, pursuant to a Special Resolution dated May 16, 2002 and a fresh Certificate of Incorporation dated October 18, 2002, the Company converted to a Public Limited, and name was changed to Max Healthcare Institute Limited'. The Company is primarily engaged in provision of healthcare services through primary care clinics, multi speciality hospitals / medical centres and superspeciality Hospitals facilities.

The Company is a leading hospital chains in India with major concentration in North India consisting of a network of 13 network healthcare facilities, which includes BLK Hospital and BNH Hospital. Besides, it provides healthcare services across secondary and tertiary care specialties with key focus on centres of excellence i.e., oncology, neurosciences, cardiac sciences, orthopaedics,renal sciences, liver and biliary sciences and minimal access metabolic and bariatric surgery (MAMBS).In addition to core hospital business, the company has two SBUs, namely, MaxHome and MaxLab. MaxHome is a platform that provides health and wellness services at home. It has 12 service lines, including pathology, pharmacy delivery, physiotherapy and critical care nursing. MaxLab offers pathology services to patients outside of hospitals through a variety of channels including third party hospital laboratory management. Eight hospitals and five medical centres are located in Delhi and the NCR, and the others are located in cities of Mumbai, Mohali, Bathinda and Dehradun. They provide diagnostic, pathology, radiology, radiation oncology and clinical services in select specialties/ departments through deployment of doctors and other medical staff in 4 Partner Healthcare Facilities.In addition, it has established a representative office in Nairobi, Kenya under the name True Max Healthcare' which helps in partnering with local hospitals, conducting OPDs, assisting the potential patients with medical visas and pre - travel preparation and participating in local events to build its brand internationally.

In the year 2000, the Company opened first Medcentre with out-patient facilities and day care surgeries at Max Medcentre, Panchsheel Park.

In the year 2002, there were facilities opened in Pitampura and Noida subject to hospital in Pitampura became the first ISO certified hospital for high-end secondary care.

In 2004, the Company opened its first super tertiary care facility with advanced cardiac life support ambulances and air evacuation service at Max Heart & Vascular Institute, Saket.

In 2005, multi-speciality tertiary care centre in East Delhi with 147 beds, three operation theatres and 1 cardiac catheterization laboratory at Max Hospital, Patparganj were opened by the Company.

In 2006, there was opening of first super speciality tertiary care location at Max Super Speciality Hospital Saket.

The Company received NABH and NABL certification for laboratories and simultaneously opened a high-end secondary care hospital at Gurgaon in the year of 2007.

The BLK Hospital was redeveloped and re-launched as a multi super speciality facility by the Company in 2009.

On 05 August 2009, through a concession agreement, the Company entered into a public private partnership (PPP) with the Department of Health and Family Welfare (DHFW), Government of Punjab and HBPL (Hometrail Buildtech Private Limited), the Company's subsidiary merged with HEPL (Hometrail Estate Private Limited), for development of greenfield super speciality hospital in Bathinda, Punjab, which was engaged in the development of greenfield super speciality hospital in Mohali, Punjab.

In 2010, the BLK Hospital received NABH accreditation and therby the Company opened a 300 bedded hospital in Shalimar Bagh.

In 2011, the Company thru HBPL, extended its footprint in North India through a public private partnership with State Government of Punjab with setting up of hospitals in Mohali and Bathinda.

In 2012, the first super speciality hospital in Uttarakhand, Max Super Speciality Hospital, Dehradun was opened and the Company's BLK Hospital installed Asia Pacific regions' first cyber-knife VSI - an ultra modern latest generation PET-CT to aid accurate diagnosis.

In 2013, the BLK Hospital commenced liver and kidney transplant services. Max Healthcare successfully performed 100 bone marrow transplant surgeries within a span of 24 months and landmark surgery on separating two conjoint Nigerian twins respectively.

On 28 May 2015, the Company acquired controlling stake in Crosslay Remedies Limited (CRL), a subsidiary that owns and operates a 378 bedded hospital with 328 operational beds, located in East Delhi-Ghaziabad-Noida corridor. The Company further had acquired 51% stake in Saket City Hospitals Private Limited, a subsidiary of the Company (SCHPL), pursuant to which it became a subsidiary in 2015.

In 2016, the company launched its vertical, Max@Home, Max Lab and India's first oncology day-care center at Lajpat Nagar to provide chemotherapy to oncology patients outside the hospital, first standalone immigration center at Lajpat Nagar, New Delhi, the Responder-on-Bike initiative, Max Centre for Liver and Biliary Sciences and oncology dedicated wing in Max Hospital Shalimar Bagh.

In 2017, Max Super Speciality Hospital, Shalimar Bagh introduced advanced silent MRI and intraoperative and portable CT scanner with navigation, it became the first hospital in the network to get accredited by the Joint Commission International (JCI).

The Company incorporated MHC Global Healthcare (Nigeria) Limited (MGHL) in Lagos, Nigeria as a wholly owned subsidiary on
May 20, 2019.

The Hon'ble National Company Law Tribunal, Mumbai Bench (NCLT) vide its order dated January 17, 2020 sanctioned the Composite Scheme of Amalgamation and Arrangement amongst erstwhile Max India Limited, the Company, Radiant, Max India Ltd. (formerly known as Advaita Allied Health Services Limited) and their respective shareholders and creditors and the Scheme was effective from June 1, 2020. Subsequent to the effective date, healthcare business of Radiant was demerged into the Company and also, residual erstwhile Max India Ltd. (i.e. post demerger of allied health and associated services into Advaita Allied Health Services Limited) which comprises of healthcare activities amalgamated with the Company. Post demerger and amalgamation, the Company became the second largest healthcare delivery chain in India (considering only income from healthcare services aggregated for Company, Radiant and Partner Healthcare Facilities). Further, pursuant to the Scheme, equity shares of the Company were listed on the BSE Limited and National Stock Exchange of India Limited (NSE) on August 21, 2020.

As on March 31, 2021, the Company has 6 subsidiaries.

The current Promoters of the Company are Mr. Analjit Singh, Ms. Neelu Analjit Singh, Ms. Piya Singh, Mr. Veer Singh, Ms. Tara Singh Vachani, MVIHPL, Mr. Abhay Soi and Kayak Investments Holding Pte. Ltd. Pursuant to Scheme, Analjit Singh Group is to be reclassified as public shareholders in accordance with the provisions of the Listing Regulations (such reclassification, the Depromoterisation). Such Depromoterisation will be undertaken only upon the Company achieving the MPS requirement as prescribed under the SCRR. Post such Depromoterisation, Mr. Abhay Soi and Kayak shall be the Promoters of the Company.

During the year 2022, the Company acquired 26% stake in Eqova Healthcare Private Limited to expand its network footprint in East Delhi with addition of 400 beds on February 10, 2022. It also entered into a long term exclusive Operation and Management Agreement with Muthoot Hospitals Private Limited for an upcoming hospital at Dwarka, New Delhi on January 20, 2022. On October 4, 2021, the Company purchased two parcels of land admeasuring ~ 5.26 acres and ~ 6.11 acres, in Gurugram, Haryana on freehold basis for setting up two hospitals and expand the bed capacity of the Company in NCR region by ~1000 beds.

Kayak Investments Holding Pte. Limited, one of the Promoters of the Company sold 27,26,754 equity shares and consequent to the open market sale, it complied with the MPS norms within the prescribed timelines i.e. with effect from August 20, 2021. As a result, at the end of FY 21-22, the public shareholding in the Company stood at 49.36%.

Pursuant to Composite Scheme of Amalgamation and Arrangement amongst erstwhile Max India Limited, the Company, Radiant Life Care Private Limited, Max India Limited (formerly known as Advaita Allied Health Services Limited) and their respective shareholders and creditors effective from June 1, 2020, certain persons / entity belonging to Promoter / Promoter Group of the Company i.e. Max Ventures Investment Holdings Private Limited, Mr. Analjit Singh, Ms. Piya Singh, Ms. Neelu Analjit Singh, Ms. Tara Singh Vachani and Mr. Veer Singh have been re-classified as Public Category with the approval accorded by stock exchanges viz. BSE Limited and National Stock Exchange of India Limited (NSE) vide their letters dated March 24, 2022. Therefore, 4,06,229 equity shares of the Company
held by the above Promoter/ Promoter Group in aggregate, representing 0.04% of its total issued and paid up capital at that time, have been re-classified into Public' from Promoters / Promoter Group' category with effect from March 24, 2022. Subsequent to re-classification of Promoter / Promoter Group, the Company has only 2 Promoters i.e. Mr. Abhay Soi and Kayak.

The Company commissioned 92-bedded Oncology Block at Max Super Speciality Hospital, in Shalimar Bagh in March, 2023. In 2023, a cloud deployment was undertaken for two key locations, including Max Lajpat Nagar and Max Panchsheel. During FY23, Max@Home, with the vision of Digital First', launched Instant Doctor Consultation service.

The year 2023-24, marked the entry of the Company into 2 new cities, Nagpur and Lucknow, adding ~750 beds to the existing bed capacity with further expansion potential. It acquired two leading healthcare institutions-200- bed at Alexis Hospital in Nagpur and 550 bed at Sahara Hospital in Lucknow, which subsequently got renamed as ' Max Super Speciality Hospitals'. Max Hospital, Dwarka, a 303 bed state of the art facility commenced its operations in mid-June, 2024; which marked a milestone to expand access to quality healthcare services.

In 2024, Company commissioned and put to operation 122 additional beds at Max Super Speciality Hospital, Shalimar Bagh, Delhi. It acquired the Shaheed Path, Lucknow with a potential to add ~550 beds. It expanded robotic surgical programs at its various Network Hospitals and conducted ~ 3500+ robotic surgeries during FY 2023-24. The Max Super Speciality Hospital - Mohali, Punjab has added the bed capacity to 155 from the existing 220 beds.

Parent organization Analjit Singh
NSE symbol MAXHEALTH
Founded 2001
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Max Healthcare Institute Ltd?

Answer Field

The share price of Max Healthcare Institute Ltd for NSE is ₹ 1098.2 and for BSE is ₹ 1098.

What is the Market Cap of Max Healthcare Institute Ltd?

Answer Field

The market cap of Max Healthcare Institute Ltd for NSE is ₹ 10,67,35.40 Cr. and for BSE is ₹ 10,67,16.00 Cr. as of now.

What is the 52 Week High and Low of Max Healthcare Institute Ltd?

Answer Field

The 52 Week High and Low of Max Healthcare Institute Ltd for NSE is ₹ 1227.95 and ₹ 743.10 and for BSE is ₹ 1227.50 and ₹ 743.00.

How to Buy Max Healthcare Institute Ltd share?

Answer Field

You can trade in Max Healthcare Institute Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Max Healthcare Institute Ltd?

Answer Field

The 1 year returns on the stock has been 30.69%.

What is the Current Share Price of Max Healthcare Institute Ltd?

Answer Field

Max Healthcare Institute Ltd share price is for NSE ₹ 1098.2 & for BSE ₹ 1098 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Max Healthcare Institute Ltd Share?

Answer Field

The market cap of Max Healthcare Institute Ltd for NSE ₹ 10,67,35.40 & for BSE ₹ 10,67,16.00 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Max Healthcare Institute Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Max Healthcare Institute Ltd share is 139.29.

What is the PB ratio of Max Healthcare Institute Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Max Healthcare Institute Ltd share is 81.72.

How to Buy Max Healthcare Institute Ltd Share?

Answer Field

You can trade in Max Healthcare Institute Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Max Healthcare Institute Ltd Share on Bajaj Broking App?

Answer Field

To buy Max Healthcare Institute Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Max Healthcare Institute Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|